Transdermal Photothermal Therapy for Obesity, Metabolic Diseases, and Body Sculpting
Despite the increasing prevalence of obesity, all FDA-approved medications, which act indirectly on the central nervous system to suppress appetite or on the gastrointestinal tract to inhibit fat absorption, suffer from poor effectiveness and side effects. Most of these medications have been withdrawn from the market. Although liposuction performed in clinics can effectively remove targeted subcutaneous fat, it suffers from invasiveness, high costs, associated risks, induction of compensatory increase of visceral fat. Although thermal lipolysis induced by high-power laser energy is a non-invasive way to reduce subcutaneous fat, its effectiveness is limited and it often causes skin burning. Both liposuction and laser lipolysis cannot improve whole-body metabolism.
The technology owner has developed a transdermal mild photothermal therapy directly acting on the root of evil, i.e. subcutaneous fat, to induce its ameliorating remodelling (browning, lipolysis, angiogenesis, and apoptosis), based on the injectable hydrogel encapsulated with photothermal agent. Browning refers to the conversion of energy-storage white fats into energy-burning brown fats. Further, combining with pharmaceutical therapy by codelivery of pharmacological agent leads to a strong therapeutic synergy. This method not only ensures high effectiveness and low side effects due to localized and targeted application but also remotely creates significant improvements in whole-body metabolism (e.g., reduction of visceral fat, relief of diabetic symptoms). In addition, this technology is applicable for cosmetic purposes, e.g., body contouring and reduction of double chin.
The technology owner is seeking potential biotechnology companies, clinicians, and other partners to clinically translate and commercialize this technology. Possible modes of collaboration include R&D, process, and product development.